Barriers to achieving asthma control in adults: evidence for the role of tiotropium in current management strategies

References

• PriceDFletcherMvan der MolenTAsthma control and management in 8,000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) surveyNPJ Prim Care Respir Med2014241400924921985
   PubMed Web of Science ®Google Scholar
• DemolyPPaggiaroPPlazaVPrevalence of asthma control among adults in France, Germany, Italy, Spain and the UKEur Respir Rev20091811210511220956130
   PubMedGoogle Scholar
• ReddelHKSawyerSMEverettPWFloodPVPetersMJAsthma control in Australia: a cross-sectional web-based survey in a nationally representative populationMed J Aust2015202949249625971575
   PubMed Web of Science ®Google Scholar
• Global Initiative for AsthmaGINA report: global strategy for asthma management and prevention Available from: http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/Accessed March 8, 2018
   Google Scholar
• HamelmannESzeflerSJEfficacy and safety of tiotropium in children and adolescentsDrugs201878332733829368127
   PubMed Web of Science ®Google Scholar
• D’AmatoMVitaleCMolinoALanzaMD’AmatoGAnticholinergic drugs in asthma therapyCurr Opin Pulm Med201723110310827820743
   PubMed Web of Science ®Google Scholar
• CazzolaMOraJRoglianiPMateraMGRole of muscarinic antagonists in asthma therapyExpert Rev Respir Med201711323925328140686
   PubMed Web of Science ®Google Scholar
• FerrandoMBagnascoDBraidoFUmeclidinium for the treatment of uncontrolled asthmaExpert Opin Investig Drugs2017266761766
   PubMed Web of Science ®Google Scholar
• AlbertsonTEChenowethJAAdamsJYSutterMEMuscarinic antagonists in early stage clinical development for the treatment of asthmaExpert Opin Investig Drugs20172613549
   PubMed Web of Science ®Google Scholar
• BusseWWDahlRJenkinsCCruzAALong-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?Eur Respir Rev201625139546426929422
   PubMed Web of Science ®Google Scholar
• HalpinDMKaplanAGRussellRKWhy choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilatorsRespir Med2017128284128610667
   PubMed Web of Science ®Google Scholar
• BarnesPJThe pharmacological properties of tiotropiumChest20001172 Suppl63S66S10673478
   PubMed Web of Science ®Google Scholar
• DisseBSpeckGARomingerKLWitekTJJrHammerRTiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung diseaseLife Sci1999646–745746410069510
   PubMed Web of Science ®Google Scholar
• HaddadEBMakJCBarnesPJCharacterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mappingMol Pharmacol19944558999078190106
   PubMed Web of Science ®Google Scholar
• RadovanovicDSantusPBlasiFManteroMThe evidence on tiotro-pium bromide in asthma: from the rationale to the bedsideMultidiscip Respir Med2017121228484598
   PubMed Web of Science ®Google Scholar
• MeursHOenemaTAKistemakerLEGosensRA new perspective on muscarinic receptor antagonism in obstructive airways diseasesCurr Opin Pharmacol201313331632323643733
   PubMed Web of Science ®Google Scholar
• GibsonPGPowellHCoughlanJSelf-management education and regular practitioner review for adults with asthmaCochrane Database Syst Rev20021CD001117
   Google Scholar
• ReddelHKJenkinsCRPartridgeMRSelf-management support and other alternatives to reduce the burden of asthma and chronic obstructive pulmonary diseaseInt J Tuberc Lung Dis201418121396140625517803
   PubMed Web of Science ®Google Scholar
• FosterJMSmithLUsherwoodTSawyerSMReddelHKGeneral practitioner-delivered adherence counseling in asthma: feasibility and usefulness of skills, training and support toolsJ Asthma201653331132026365203
   PubMed Web of Science ®Google Scholar
• CharriotJVachierIHalimiLFuture treatment for asthmaEur Respir Rev201625139779226929425
   PubMed Web of Science ®Google Scholar
• ZolnierekKBDimatteoMRPhysician communication and patient adherence to treatment: a meta-analysisMed Care200947882683419584762
   PubMed Web of Science ®Google Scholar
• WesterikJACarterVChrystynHCharacteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care settingJ Asthma201653332132926810934
   PubMed Web of Science ®Google Scholar
• JahediLDownieSRSainiBChanHKBosnic-AnticevichSInhaler technique in asthma: how does it relate to patients’ preferences and attitudes toward their inhalers?J Aerosol Med Pulm Drug Deliv2017301425227676193
   PubMed Web of Science ®Google Scholar
• CromptonGKBarnesPJBroedersMThe need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement TeamRespir Med200610091479149416495040
   PubMed Web of Science ®Google Scholar
• LavoriniFLevyMLCorriganCCromptonGADMIT Working GroupThe ADMIT series – issues in inhalation therapy. 6) Training tools for inhalation devicesPrim Care Respir J201019433534121049263
   PubMedGoogle Scholar
• CraneMAJenkinsCRGoemanDPDouglassJAInhaler device technique can be improved in older adults through tailored education: findings from a randomised controlled trialNPJ Prim Care Respir Med2014241403425188403
   PubMed Web of Science ®Google Scholar
• ResnickDJGoldRLLee-WongMFeldmanBRRamakrishnanRDavisWJPhysicians’ metered dose inhaler technique after a single teaching sessionAnn Allergy Asthma Immunol19967621451488595532
   PubMed Web of Science ®Google Scholar
• BashetiIAThe effect of using simulation for training pharmacy students on correct device techniqueAm J Pharm Educ2014781017725657364
   PubMed Web of Science ®Google Scholar
• DalbyRNEicherJZierenbergBDevelopment of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disordersMed Devices (Auckl)2011414515522915941
   PubMedGoogle Scholar
• Moroni-ZentgrafPImpact of patient needs on design and usage of an inhalation device in respiratory medicineRespir Drug Deliv20131141
   Google Scholar
• KerstjensHAEngelMDahlRTiotropium in asthma poorly controlled with standard combination therapyN Engl J Med2012367131198120722938706
   PubMed Web of Science ®Google Scholar
• KerstjensHACasaleTBBleeckerERTiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trialsLancet Respir Med20153536737625682232
   PubMed Web of Science ®Google Scholar
• PaggiaroPHalpinDMBuhlRThe effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trialJ Allergy Clin Immunol Pract20164110411326563670
   PubMed Web of Science ®Google Scholar
• OhtaKIchinoseMTohdaYLong-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled studyPLoS One2015104e012410925894430
   PubMed Web of Science ®Google Scholar
• HamelmannEBatemanEDVogelbergCTiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trialJ Allergy Clin Immunol2016138244145026960245
   PubMed Web of Science ®Google Scholar
• VogelbergCEngelMLakiITiotropium add-on therapy improves lung function in children with symptomatic moderate asthmaJ Allergy Clin Immunol Pract Epub2018508
   PubMed Web of Science ®Google Scholar
• HamelmannEBernsteinJAVandewalkerMA randomised controlled trial of tiotropium in adolescents with severe symptomatic asthmaEur Respir J2017491160110027811070
   PubMed Web of Science ®Google Scholar
• SzeflerSJMurphyKHarperT3rdA Phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthmaJ Allergy Clin Immunol201714051277128728189771
   PubMed Web of Science ®Google Scholar
• BisgaardHVandewalkerMGrahamLMSafety of tiotropium in pre-school children with symptomatic persistent asthmaEur Respir J201648Suppl 60PA315
   Google Scholar
• VogelbergCLakiISchmidtOSafety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthmaEur Respir J201648Suppl 60PA4399
   Google Scholar
• DahlREngelMDusserDSafety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysisRespir Med201611810211127578478
   PubMed Web of Science ®Google Scholar
• AndersonDEKewKMBoyterACLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthmaCochrane Database Syst Rev2015248CD011397
   Google Scholar
• KewKMDahriKLong-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthmaCochrane Database Syst Rev2016211CD011721
   Google Scholar
• RodrigoGJCastro-RodríguezJAWhat is the role of tiotropium in asthma?: a systematic review with meta-analysisChest2015147238839625322075
   PubMed Web of Science ®Google Scholar
• PetersSPKunselmanSJIcitovicNTiotropium bromide step-up therapy for adults with uncontrolled asthmaN Engl J Med2010363181715172620979471
   PubMed Web of Science ®Google Scholar
• AbadogluOBerkSTiotropium may improve asthma symptoms and lung function in asthmatic patients with irreversible airway obstruction: the real-life dataClin Respir J201610442142725335652
   PubMed Web of Science ®Google Scholar
• PriceDKaplanAJonesRLong-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromideJ Asthma Allergy2015811325609985
   PubMed Web of Science ®Google Scholar
• PaggiaroPBacciEMontelukast in asthma: a review of its efficacy and place in therapyTher Adv Chronic Dis201121475823251741
   PubMedGoogle Scholar
• Peters-GoldenMHendersonWRJrLeukotrienesN Engl J Med2007357181841185417978293
   PubMed Web of Science ®Google Scholar
• JoosSMikschASzecsenyiJMontelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic reviewThorax200863545346218443162
   PubMed Web of Science ®Google Scholar
• RobinsonDSCampbellDBarnesPJAddition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trialLancet200135792732007201111438132
   PubMed Web of Science ®Google Scholar
• TonelliMZingoniMBacciEShort-term effect of the addition of leukotriene receptor antagonists to the current therapy in severe asthmaticsPulm Pharmacol Ther200316423724012850127
   PubMed Web of Science ®Google Scholar
• ChauhanBFDucharmeFMAddition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthmaCochrane Database Syst Rev2014241CD003137
   Google Scholar
• MarcelloCCarloLAsthma phenotypes: the intriguing selective intervention with montelukastAsthma Res Pract201621127965779
   PubMedGoogle Scholar
• PaggiaroPLGianniniDDi FrancoATestiRComparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study GroupEur Respir J199698168916958866596
   PubMed Web of Science ®Google Scholar
• DahlRLarsenBBVengePEffect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptomsRespir Med200296643243812117043
   PubMed Web of Science ®Google Scholar
• BarnesPJTheophyllineAm J Respir Crit Care Med2013188890190623672674
   PubMed Web of Science ®Google Scholar
• UkenaDHarnestUSakalauskasRComparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthmaEur Respir J19971012275427609493656
   PubMed Web of Science ®Google Scholar
• LiJKangJWangCOmalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized Phase III studyAllergy Asthma Immunol Res20168431932827126725
   PubMed Web of Science ®Google Scholar
• BjermerLLemiereCMasperoJWeissSZangrilliJGerminaroMReslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized Phase 3 studyChest2016150478979827056586
   PubMed Web of Science ®Google Scholar
• OrtegaHGLiuMCPavordIDMepolizumab treatment in patients with severe eosinophilic asthmaN Engl J Med2014371131198120725199059
   PubMed Web of Science ®Google Scholar
• WenzelSCastroMCorrenJDupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal Phase 2b dose-ranging trialLancet201638810039314427130691
   PubMed Web of Science ®Google Scholar
• PavordIDKornSHowarthPMepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialLancet2012380984265165922901886
   PubMed Web of Science ®Google Scholar
• RubinAZelmanovitzSCavalcantiMBronchial thermoplasty in a patient with difficult-to-control asthmaJ Bras Pneumol201642215515627167438
   PubMed Web of Science ®Google Scholar
• WahidiMMKraftMBronchial thermoplasty for severe asthmaAm J Respir Crit Care Med2012185770971422077066
   PubMed Web of Science ®Google Scholar
• CasaleTBBatemanEDVandewalkerMTiotropium Respimat add-on is efficacious in symptomatic asthma, independent of T2 phenotypeJ Allergy Clin Immunol Pract20186392393529174062
   PubMed Web of Science ®Google Scholar
• KerstjensHAMoroni-ZentgrafPTashkinDPTiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic statusRespir Med201611719820627492532
   PubMed Web of Science ®Google Scholar
• CasaleTBBatemanEDAalbersROnce-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristicsEur Respir J201750PA647
   Web of Science ®Google Scholar
• BouletLPAsthma and obesityClin Exp Allergy201343182123278876
   PubMed Web of Science ®Google Scholar
• TaylorBManninoDBrownCCrockerDTwum-BaahNHolguinFBody mass index and asthma severity in the National Asthma SurveyThorax2008631142018156567
   PubMed Web of Science ®Google Scholar
• KhuranaSKerstjensHAPaggiaroPOnce-daily tiotropium Respimat® add-on to inhaled corticosteroid maintenance therapy reduces airflow obstruction in patients with symptomatic asthma, independent of body mass index scoreAm J Respir Crit Care Med2017195A6443
   Web of Science ®Google Scholar
• WechslerMECastroMLehmanEImpact of race on asthma treatment failures in the asthma clinical research networkAm J Respir Crit Care Med2011184111247125321885625
   PubMed Web of Science ®Google Scholar
• WechslerMEYawnBPFuhlbriggeALAnticholinergic vs long-acting β-agonist in combination with inhaled corticosteroids in black adults with asthma: the BELT randomized clinical trialJAMA2015314161720173026505596
   PubMed Web of Science ®Google Scholar
• OrtegaVEHawkinsGAMooreWCEffect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic studyLancet Respir Med20142320421324621682
   PubMed Web of Science ®Google Scholar
• WechslerMEKunselmanSJChinchilliVMEffect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trialLancet200937497031754176419932356
   PubMed Web of Science ®Google Scholar
• PalmerCNLipworthBJLeeSIsmailTMacgregorDFMukhopadhyaySArginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterolThorax2006611194094416772309
   PubMed Web of Science ®Google Scholar
• BatemanEDKornmannOSchmidtPPivovarovaAEngelMFabbriLMTiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthmaJ Allergy Clin Immunol2011128231532221807250
   PubMed Web of Science ®Google Scholar
• GrahamLKerstjensHAVogelbergCSafety and tolerability of once-daily tiotropium Respimat® add-on therapy in African-American patients with symptomatic persistent asthma across a range of severitiesAm J Respir Crit Care Med2017195A6445
   Web of Science ®Google Scholar
• NunesCPereiraAMMorais-AlmeidaMAsthma costs and social impactAsthma Res Pract20173128078100
   PubMedGoogle Scholar
• WillsonJBatemanEDPavordILloydAKrivasiTEsserDCost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonistsAppl Health Econ Health Policy201412444745924974107
   PubMedGoogle Scholar
• WillsonJBatemanEDPavordILloydAKrivasiTEsserDErratum to: Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonistsAppl Health Econ Health Policy201614111912526816028
   PubMed Web of Science ®Google Scholar
• ZafariZSadatsafaviMFitzGeraldJMCanadian Respiratory Research NetworkCost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in USCost Eff Resour Alloc2018161329422778
   PubMed Web of Science ®Google Scholar